Season 2 - Episode 12: Immune checkpoint inhibitors and the heart - HDL, HDL therapies and cardiovascular risk

Mar 28, 2024

Guest

Carlos Aguiar

Guest

Francois Mach

Guest

Alexander Lyon

Experts in cardiology discuss immune checkpoint inhibitors and their impacts on the heart, the importance of HDL and its therapies for cardiovascular health, and the FBI syndrome. Topics include cardiovascular complications of immune checkpoint inhibitors, strategies to elevate HDL levels, and enhancing HDL carriers. The podcast also covers recent key studies in cardiology.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 6min

Immune Checkpoint Inhibitors and Cardiovascular Side Effects

05:41 • 6min

Exploring the Role of HDL in Atherosclerosis and Cardiovascular Risk Reduction

11:40 • 2min

Exploring HDL Cholesterol and Cardiovascular Risk Reduction through Apolipoprotein A1 Enhancement

13:25 • 2min

Hope for HDL Interventions and FBI Syndrome in Cardiology

15:38 • 5min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies
Immune checkpoint inhibitors and the heart
HDL, HDL therapies and cardiovascular risk
Diagnostics Made Easy: the FBI syndrome

Host: Susanna Price

Guests: Carlos Aguiar, Alexander Lyon, Francois Mach

Want to watch that episode? Go to: https://esc365.escardio.org/event/1147

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Francois Mach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic.

Alexander Lyon has declared to receive speaker, advisory board or consultancy fees and/or research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.